Species differences in intestinal metabolic activities of Cytochrome P450 isoforms between cynomolgus monkeys and humans

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 3, 2011, Pages 300-306

  Nishimuta, Haruka ^a   Sato, Kimihiko ^a   Mizuki, Yasuyuki ^a   Yabuki, Masashi ^a   Komuro, Setsuko ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Cynomolgus monkey; CYP2C; CYP4F; Cytochrome P450; Intestinal first pass metabolism; Species differences

Indexed keywords

AMODIAQUINE; ASTEMIZOLE; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 2J2; ISOPROTEIN; LANSOPRAZOLE; TERFENADINE;

AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME METABOLISM; ENZYME SUBSTRATE; EXPERIMENTAL MONKEY; FIRST PASS EFFECT; HAPLORHINI; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; INTESTINE CELL; MALE; MICROSOME; NONHUMAN; PRESCHOOL CHILD; SPECIES DIFFERENCE;

EID: 79960023245     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-SH-119     Document Type: Article

References (21)

1. Takahashi, M., Washio, T., Suzuki, N., Igeta, K. and Yamashita, S.: The species differences of intestinal drug absorption and firstpass metabolism between cynomolgus monkeys and humans. J. Pharm. Sci., 98: 4343-4353 (2009).
2. Sakuda, S., Akabane, T. and Teramura, T.: Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica, 36: 331-340 (2006).
3. Nishimuta, H., Sato, K., Mizuki, Y., Yabuki, M. and Komuro, S.: Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab. Dispos., 38: 1967-1975 (2010).
4. Ogasawara, A., Kume, T. and Kazama, E.: Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab. Dispos., 35: 410-418 (2007).
5. Pelkonen, O.: Human CYPs: in vivo and clinical aspects. Drug Metab. Rev., 34: 37-46 (2002).
6. Lewis, D. F.: Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: A compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr. Med. Chem., 10: 1955-1972 (2003).
7. Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E. and Zeldin, D. C.: The human intestinal cytochrome P450 úpieû. Drug Metab. Dispos., 34: 880-886 (2006).
8. Wang, M. Z., Wu, J. Q., Bridges, A. S., Zeldin, D. C., Kornbluth, S., Tidwell, R. R., Hall, J. E. and Paine, M. F.: Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab. Dispos., 35: 2067-2075 (2007).
9. Uno, Y., Fujino, H., Kito, G., Kamataki, T. and Nagata, R.: CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Mol. Pharmacol., 70: 477-486 (2006).
10. Uno, Y., Hosaka, S., Matsuno, K., Nakamura, C., Kito, G., Kamataki, T. and Nagata, R.: Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch. Biochem. Biophys., 466: 98-105 (2007).
11. Uno, Y., Uehara, S., Kohara, S., Murayama, N. and Yamazaki, H.: Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Drug Metab. Dispos., 38: 1486-1492 (2010).
12. Zou, A. P., Ma, Y. H., Sui, Z. H., Ortiz de Montellano, P. R., Clark, J. E., Masters, B. S. and Roman, R. J.: Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. J. Pharmacol. Exp. Ther., 268: 474-481 (1994).
13. Lisitsa, A., Archakov, A., Lewi, P. and Janssen, P.: Bioinformatic insight into the unity and diversity of cytochromes P450. Methods Find. Exp. Clin. Pharmacol., 25: 733-745 (2003).
14. Nishimura, T., Amano, N., Kubo, Y., Ono, M., Kato, Y., Fujita, H., Kimura, Y. and Tsuji, A.: Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab. Dispos., 35: 1275-1284 (2007).
15. Hashizume, T., Mise, M., Matsumoto, S., Terauchi, Y., Fujii, T., Imaoka, S., Funae, Y., Kamataki, T. and Miyazaki, H.: A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab. Dispos., 29: 798-805 (2001).
16. Zhou, S. F., Liu, J. P. and Chowbay, B.: Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 41: 89-295 (2009).
17. Powell, P. K., Wolf, I., Jin, R. and Lasker, J. M.: Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther., 285: 1327-1336 (1998).
18. Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T. and Funae, Y.: Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther., 300: 298-304 (2002).
19. Iwasaki, K. and Uno, Y.: Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica, 39: 578-581 (2009).
20. Matsumoto, S., Hirama, T., Matsubara, T., Nagata, K. and Yamazoe, Y.: Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos., 30: 1240-1245 (2002).
21. Lafite, P., Dijols, S., Buisson, D., Macherey, A. C., Zeldin, D. C., Dansette, P. M. and Mansuy, D.: Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg. Med. Chem. Lett., 16: 2777-2780 (2006).